7fjs: Difference between revisions
New page: '''Unreleased structure''' The entry 7fjs is ON HOLD Authors: Wang, X., Zhang, L., Zhang, S., Liang, Q. Description: Crystal structure of T6 Fab bound to theSARS-CoV-2 RBD of B.1.351 [... |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Crystal structure of T6 Fab bound to theSARS-CoV-2 RBD of B.1.351== | |||
<StructureSection load='7fjs' size='340' side='right'caption='[[7fjs]], [[Resolution|resolution]] 2.90Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[7fjs]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome_coronavirus_2 Severe acute respiratory syndrome coronavirus 2]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7FJS OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7FJS FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.9Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7fjs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7fjs OCA], [https://pdbe.org/7fjs PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7fjs RCSB], [https://www.ebi.ac.uk/pdbsum/7fjs PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7fjs ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
With the rapid emergence and spread of SARS-CoV-2 variants, development of vaccines with broad and potent protectivity has become a global priority. Here, we designed a lipid nanoparticle-encapsulated, nucleoside-unmodified mRNA (mRNA-LNP) vaccine encoding the trimerized receptor-binding domain (RBD trimer) and showed its robust capability in inducing broad and protective immune responses against wild-type and major variants of concern (VOCs) in the mouse model of SARS-CoV-2 infection. The protectivity was correlated with RBD-specific B cell responses especially the long-lived plasma B cells in bone marrow, strong ability in triggering BCR clustering, and downstream signaling. Monoclonal antibodies isolated from vaccinated animals demonstrated broad and potent neutralizing activity against VOCs tested. Structure analysis of one representative antibody identified a novel epitope with a high degree of conservation among different variants. Collectively, these results demonstrate that the RBD trimer mRNA vaccine serves as a promising vaccine candidate against SARS-CoV-2 variants and beyond. | |||
RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants.,Liang Q, Wang Y, Zhang S, Sun J, Sun W, Li J, Liu Y, Li M, Cheng L, Jiang Y, Wang R, Zhang R, Yang Z, Ren Y, Chen P, Gao P, Yan H, Zhang Z, Zhang Q, Shi X, Wang J, Liu W, Wang X, Ying B, Zhao J, Qi H, Zhang L iScience. 2022 Apr 15;25(4):104043. doi: 10.1016/j.isci.2022.104043. Epub 2022 , Mar 11. PMID:35291264<ref>PMID:35291264</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: | <div class="pdbe-citations 7fjs" style="background-color:#fffaf0;"></div> | ||
[[Category: | |||
[[Category: Liang | ==See Also== | ||
[[Category: Wang | *[[Spike protein 3D structures|Spike protein 3D structures]] | ||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | |||
[[Category: Severe acute respiratory syndrome coronavirus 2]] | |||
[[Category: Liang Q]] | |||
[[Category: Wang X]] | |||
[[Category: Zhang L]] | |||
[[Category: Zhang S]] | |||
Latest revision as of 12:25, 9 October 2024
Crystal structure of T6 Fab bound to theSARS-CoV-2 RBD of B.1.351Crystal structure of T6 Fab bound to theSARS-CoV-2 RBD of B.1.351
Structural highlights
Publication Abstract from PubMedWith the rapid emergence and spread of SARS-CoV-2 variants, development of vaccines with broad and potent protectivity has become a global priority. Here, we designed a lipid nanoparticle-encapsulated, nucleoside-unmodified mRNA (mRNA-LNP) vaccine encoding the trimerized receptor-binding domain (RBD trimer) and showed its robust capability in inducing broad and protective immune responses against wild-type and major variants of concern (VOCs) in the mouse model of SARS-CoV-2 infection. The protectivity was correlated with RBD-specific B cell responses especially the long-lived plasma B cells in bone marrow, strong ability in triggering BCR clustering, and downstream signaling. Monoclonal antibodies isolated from vaccinated animals demonstrated broad and potent neutralizing activity against VOCs tested. Structure analysis of one representative antibody identified a novel epitope with a high degree of conservation among different variants. Collectively, these results demonstrate that the RBD trimer mRNA vaccine serves as a promising vaccine candidate against SARS-CoV-2 variants and beyond. RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants.,Liang Q, Wang Y, Zhang S, Sun J, Sun W, Li J, Liu Y, Li M, Cheng L, Jiang Y, Wang R, Zhang R, Yang Z, Ren Y, Chen P, Gao P, Yan H, Zhang Z, Zhang Q, Shi X, Wang J, Liu W, Wang X, Ying B, Zhao J, Qi H, Zhang L iScience. 2022 Apr 15;25(4):104043. doi: 10.1016/j.isci.2022.104043. Epub 2022 , Mar 11. PMID:35291264[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||